Antiverse Raises $9.3M Series A for AI Antibody Discovery
UK-based Antiverse has secured $9.3 million in Series A funding to advance its AI-driven platform for designing therapeutic antibodies targeting hard-to-treat diseases. The investment will support the company's platform development, drug pipeline expansion, and collaborative research efforts.